Murray, chief executive officer of ACAP. ‘We are very happy to welcome them into our company and have them as a preferred vendor.’ ArpegioHealth works together with senior leaders to develop integrated solutions to solve complex problems linked to growth and switch. ArpegioHealth has a track record of successfully helping nationwide clients achieve sustainable results and higher degrees of performance. ‘There are numerous new opportunities coming for ACAP people to explore,’ said Dr. Carol J. Geffner, CEO of ArpegioHealth. ‘Whether it’s through medical health insurance exchanges, accountable care companies or various other innovative systems, back-up programs are well positioned to develop and enhance their ability to serve their communities.’..The record, entitled ‘Cardiovascular Advertising: Budgets, Strategy and Staffing,’ available online, highlights the necessity of being in a position to adapt to the fast and constant change seen in the pharmaceutical cardiovascular marketplace. Pharmaceutical companies spend more to support a cardiovascular compound’s development and commercialization than they perform on any other therapeutic products. Among best drug makers, product sales from cardiovascular medications may contribute from 20 percent to 50 percent of annual pharmaceutical revenues. Because of the great expenditure of developing cardiovascular medications, top pharmaceutical businesses are shifting away from developing fresh anti-anginal medicines for cardiovascular diseases.